PFE
Pfizer Inc.
PFE
Pfizer Inc.
Pfizer (PFE) remains a strong buy as guidance is reaffirmed and raised, with acquired assets compounding at 18% operationally. PFE's pipeline strength is evident, especially in obesity (berobenatide)
Pfizer remains a cautious Buy, trading near intrinsic value with an expected 10% annual return, primarily from its high dividend yield. PFE faces significant headwinds: a looming patent cliff, a stret
Pfizer Inc. (NYSE:PFE) will release its second quarter earnings report before the opening bell on Tuesday, Aug. 4.
The deal could create one of the world's biggest pharmaceutical groups with a combined value of nearly $400 billion.
SpaceX (SPCX) will deliver its first public earnings report, with focus on Starlink growth, Starship timeline, and capital spending. SPCX shares have fallen over 50% from peak and are 20% below the IP
Markets face a pivotal week as jobs data, Fed speakers and earnings from SpaceX, AMD and Palantir test sentiment and the AI outlook.
Pfizer's non-COVID commercial portfolio is accelerating, with new launches and business development products growing 22% to a nearly $12 billion annualized run rate. Seagen's oncology portfolio expand
Eli Lilly and Company, Abbott Laboratories, AbbVie, Novo Nordisk A/S, Pfizer, Bristol Myers Squibb, and Gilead Sciences are the seven Pharmaceutical stocks to watch today, according to MarketBeat's st
Pfizer remains an undervalued diversification play, underperforming the benchmark but increasing 2% since prior coverage. I view PFE as a defensive holding that pays investors to maintain a cautious s
Pfizer is undervalued, trading at just over 8x 2026 earnings, with a 7% dividend yield and improving core business fundamentals. Core business excluding COVID drugs grew 7% in Q1, and newly launched/a
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) shares are trading higher in Monday's after-hours session after the company announced it will be acquired by Vertex Pharmaceuticals Inc (NASDAQ:VRTX).
Zoetis has seen its valuation compress dramatically, now trading at just 12x trailing earnings after a 52% 12-month share price decline. Despite decelerating growth—Q1 2026 saw just 3% revenue growth—